

# Giovanni D'Arena

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4219037/publications.pdf>

Version: 2024-02-01

108  
papers

1,981  
citations

304743

22  
h-index

289244

40  
g-index

108  
all docs

108  
docs citations

108  
times ranked

2932  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. <i>Tumor Biology</i> , 2015, 36, 9739-9752.          | 1.8 | 159       |
| 2  | CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. <i>Blood</i> , 2007, 110, 4012-4021.  | 1.4 | 149       |
| 3  | Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. <i>Leukemia Research</i> , 2011, 35, 363-368.   | 0.8 | 128       |
| 4  | Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. <i>American Journal of Hematology</i> , 2006, 81, 598-602.   | 4.1 | 93        |
| 5  | Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. <i>American Journal of Hematology</i> , 2000, 64, 275-281.   | 4.1 | 91        |
| 6  | Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. <i>European Journal of Haematology</i> , 2007, 79, 53-58.   | 2.2 | 71        |
| 7  | MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 97-103.                                     | 4.4 | 65        |
| 8  | Clinical Pharmacology of <i>Citrus aurantium</i> and <i>Citrus sinensis</i> for the Treatment of Anxiety. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-18.                                | 1.2 | 53        |
| 9  | CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. <i>Blood</i> , 2013, 122, 3317-3321.  | 1.4 | 48        |
| 10 | Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-9.  | 1.5 | 44        |
| 11 | SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. <i>Journal of Clinical Investigation</i> , 2015, 126, 181-194.   | 8.2 | 44        |
| 12 | HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. <i>Haematologica</i> , 2014, 99, 888-896.          | 3.5 | 43        |
| 13 | Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1424-1432.   | 1.3 | 43        |
| 14 | SPONTANEOUS REMISSION IN ACUTE MYELOID LEUKAEMIA: A ROLE FOR ENDOGENOUS PRODUCTION OF TUMOUR NECROSIS FACTOR AND INTERLEUKIN-2?. <i>British Journal of Haematology</i> , 1994, 87, 879-880.                               | 2.5 | 41        |
| 15 | Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2007, 82, 787-791.   | 4.1 | 39        |
| 16 | CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020, 135, 1244-1254.  | 1.4 | 33        |
| 17 | A shorter time to the first treatment may be predicted by the absolute number of regulatory T cells in patients with Rai stage 0 chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2012, 87, 628-631. | 4.1 | 32        |
| 18 | Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 1072-1080.  | 1.3 | 30        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. <i>Leukemia Research</i> , 2015, 39, 1066-1070.   | 0.8 | 29        |
| 20 | Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies. <i>Journal of Immunology Research</i> , 2017, 2017, 1-13.   | 2.2 | 29        |
| 21 | Role of Viral miRNAs and Epigenetic Modifications in Epstein-Barr Virus-Associated Gastric Carcinogenesis. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-11.  | 4.0 | 26        |
| 22 | Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study. <i>Stem Cell Research and Therapy</i> , 2015, 6, 64. | 5.5 | 25        |
| 23 | The Effect of Light Exposure at Night (LAN) on Carcinogenesis via Decreased Nocturnal Melatonin Synthesis. <i>Molecules</i> , 2018, 23, 1308.  | 3.8 | 25        |
| 24 | Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. <i>Leukemia</i> , 2020, 34, 462-477.   | 7.2 | 24        |
| 25 | No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura. <i>Blood</i> , 2013, 121, 1240-1242.   | 1.4 | 23        |
| 26 | TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 5566-5575.  | 7.0 | 23        |
| 27 | Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia. <i>European Journal of Haematology</i> , 2009, 82, 235-239.  | 2.2 | 22        |
| 28 | Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. <i>European Journal of Haematology</i> , 2010, 85, 502-507.  | 2.2 | 22        |
| 29 | NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. <i>British Journal of Haematology</i> , 2018, 182, 597-602.   | 2.5 | 22        |
| 30 | CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2018, 36, 543-546.  | 1.7 | 21        |
| 31 | The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A. <i>Blood Transfusion</i> , 2016, 14, 255-61.  | 0.4 | 21        |
| 32 | Chronic Lymphoproliferative Disorders: An Integrated Point of View for the Differential Diagnosis. <i>Leukemia and Lymphoma</i> , 2000, 36, 225-237.   | 1.3 | 20        |
| 33 | Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia. <i>Leukemia and Lymphoma</i> , 2011, 52, 701-704.   | 1.3 | 19        |
| 34 | Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 2633-2641.   | 1.3 | 19        |
| 35 | Metabolic Syndrome, Insulin Resistance, Circadian Disruption, Antioxidants and Pancreatic Carcinoma: an Overview. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 23, 73-77.   | 0.9 | 19        |
| 36 | Mutations in the 3' untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e305-e309.  | 3.5 | 18        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498. <i>Expert Opinion on Therapeutic Patents</i> , 2014, 24, 821-828.  | 5.0 | 17        |
| 38 | Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. <i>Leukemia and Lymphoma</i> , 2014, 55, 841-847.                                 | 1.3 | 17        |
| 39 | Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander?. <i>American Journal of Blood Research</i> , 2013, 3, 52-7.  | 0.6 | 17        |
| 40 | Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Na <sup>+</sup> -ve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Cancers</i> , 2019, 11, 896.                 | 3.7 | 16        |
| 41 | Fournier's Gangrene Complicating Hematologic Malignancies: Literature Review and Treatment Suggestions. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013067.             | 1.3 | 15        |
| 42 | Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role. <i>Journal of Immunology Research</i> , 2016, 2016, 1-7.                     | 2.2 | 15        |
| 43 | A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1613-1620.  | 3.5 | 15        |
| 44 | Venetoclax in CLL patients who progress after B <sup>+</sup> cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. <i>British Journal of Haematology</i> , 2019, 187, e8-e11. | 2.5 | 14        |
| 45 | CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance. <i>Frontiers in Oncology</i> , 2020, 10, 584427.   | 2.8 | 14        |
| 46 | REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012053.   | 1.3 | 12        |
| 47 | Autoimmune Cytopenias in Chronic Lymphocytic Leukemia. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.  | 3.3 | 12        |
| 48 | Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 2017, 99, 306-314.  | 2.2 | 12        |
| 49 | &lt;p&gt;Dissecting the prevention of estrogen-dependent breast carcinogenesis through Nrf2-dependent and independent mechanisms&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4937-4953.    | 2.0 | 12        |
| 50 | &lt;i&gt;SF3B1&lt;/i&gt;-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. <i>Haematologica</i> , 2021, 106, 3125-3135.                       | 3.5 | 12        |
| 51 | Chronic Lymphocytic Leukemia After Chronic Myeloid Leukemia in the Same Patient: Two Different Genomic Events and a Common Treatment?. <i>Journal of Clinical Oncology</i> , 2012, 30, e327-e330.           | 1.6 | 11        |
| 52 | Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e443-e446.  | 3.5 | 11        |
| 53 | Oxidative stress in chronic lymphocytic leukemia: still a matter of debate. <i>Leukemia and Lymphoma</i> , 2019, 60, 867-875.   | 1.3 | 11        |
| 54 | Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2008, 8, 62-68.   | 1.2 | 10        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 55 | Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience. <i>Leukemia and Lymphoma</i> , 2016, 57, 2429-2431.   | 1.3  | 10        |
| 56 | Guillain-Barré Syndrome Complicating Mobilization Therapy in a Case of B-cell Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 1489-1490.   | 1.3  | 9         |
| 57 | Myelodysplastic disorders carrying both isolated del(5q) and JAK2V617F mutation: concise review, with focus on lenalidomide therapy. <i>OncoTargets and Therapy</i> , 2014, 7, 1043.                                    | 2.0  | 9         |
| 58 | Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. <i>Haematologica</i> , 2017, 102, e352-e355. | 3.5  | 9         |
| 59 | CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results. <i>Leukemia Research</i> , 2019, 83, 106169.  | 0.8  | 8         |
| 60 | Serum levels of soluble calreticulin predict for time to first treatment in early chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2016, 175, 983-985.  | 2.5  | 7         |
| 61 | NOTCH1 Mutated IGHV Unmutated Chronic Lymphocytic Leukemia Cells Are Characterized By a Constitutive Overexpression of Nucleophosmin-1 and Ribosome-Associated Components. <i>Blood</i> , 2014, 124, 3308-3308.         | 1.4  | 6         |
| 62 | NOTCH1 Mutations Are Associated with Low CD20 Expression in Chronic Lymphocytic Leukemia: Evidences for a NOTCH1-Mediated Epigenetic Regulatory Mechanism. <i>Blood</i> , 2014, 124, 296-296.                           | 1.4  | 5         |
| 63 | An Urologic Face of Chronic Lymphocytic Leukemia: Sequential Prostatic and Penis Localization. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013008.                                  | 1.3  | 4         |
| 64 | Fournier's gangrene complicating thrombocytopenia treated with steroids. <i>Lancet, The</i> , 2014, 383, 1580.  | 13.7 | 4         |
| 65 | Acquired Hemophilia A successfully treated with rituximab. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015, 7, e2015024.  | 1.3  | 4         |
| 66 | External validation of the accuracy of $\hat{c}$ CLLflow score <sup>TM</sup> . <i>Journal of Investigative Medicine</i> , 2018, 66, e6-e6.  | 1.6  | 4         |
| 67 | Cytofluorimetric and immunohistochemical comparison for detecting bone marrow infiltration in non-Hodgkin lymphomas: a study of 354 patients. <i>Leukemia Research</i> , 2020, 88, 106267.                              | 0.8  | 4         |
| 68 | Heterogeneity of clinical and radiological findings of COVID-19. <i>Postgraduate Medical Journal</i> , 2021, 97, 268-269.   | 1.8  | 4         |
| 69 | Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics. <i>Hematological Oncology</i> , 2022, 40, 469-474.                 | 1.7  | 4         |
| 70 | DAT-negative hemolytic anemia in a chronic lymphocytic leukemia patient treated with alemtuzumab. <i>Leukemia and Lymphoma</i> , 2007, 48, 625-627.   | 1.3  | 3         |
| 71 | Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells. <i>Leukemia and Lymphoma</i> , 2015, 56, 2458-2459.   | 1.3  | 3         |
| 72 | Monoclonal B-cell lymphocytosis and prostate cancer: Incidence and effects of radiotherapy. <i>Journal of Investigative Medicine</i> , 2019, 67, 779-782.   | 1.6  | 3         |

| #  | ARTICLE   | IF         | CITATIONS |
|----|---|------------|-----------|
| 73 | Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the Tj ETQq1 1.0.784314 rgBT /Ov | 1.0.784314 | 1         |
| 74 | Improvement of B-Cell Chronic Lymphocytic Leukemia During Haemodialysis: Possible Role for Endogenous Production of Factors Involved in Angiogenesis and Apoptosis?. Leukemia and Lymphoma, 2003, 44, 1263-1265.                            | 1.3        | 2         |
| 75 | Heavy/light chain ratio for the assessment of minimal residual disease in myeloma patients achieving complete response. British Journal of Haematology, 2018, 181, 550-552.   | 2.5        | 2         |
| 76 | Thalidomide-induced psoriasis in a patient with multiple myeloma. Postgraduate Medical Journal, 2019, 95, 171-171.  | 1.8        | 2         |
| 77 | <p>Atypical Mature T-Cell Neoplasms: The Relevance of the Role of Flow Cytometry</p>. OncoTargets and Therapy, 2020, Volume 13, 7605-7614.  | 2.0        | 2         |
| 78 | Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party. Blood, 2019, 134, 2931-2931.  | 1.4        | 2         |
| 79 | LDH Levels Predict Progression-Free Survival in Treatment-Naïve Patients with Trisomy 12 Chronic Lymphocytic Leukemia. Blood, 2016, 128, 3211-3211.   | 1.4        | 2         |
| 80 | Quantitative Evaluation of CD52 Expression in B-Cell Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 2003, 44, 1255-1257.  | 1.3        | 1         |
| 81 | Darier sign and cutaneous involvement in mastocytosis. British Journal of Haematology, 2014, 167, 440-440.  | 2.5        | 1         |
| 82 | Meningeal Involvement in Primary Plasma Cell Leukemia. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 556-557.   | 0.6        | 1         |
| 83 | Parietal skull extramedullary relapse in multiple myeloma. Postgraduate Medical Journal, 2020, 96, 360-360.   | 1.8        | 1         |
| 84 | CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia. Cancers, 2021, 13, 4239.   | 3.7        | 1         |
| 85 | A CRISPR/Cas9-Generated Murine Model Reveals Cooperation between BCR Signaling and CDKN2A/2B and TP53 Disruption in Richter Syndrome. Blood, 2019, 134, 4278-4278.  | 1.4        | 1         |
| 86 | SARS-COV2 Infection in Vaccinated Patients: Look for Clinical History and Test Humoral Immunity. Indian Journal of Hematology and Blood Transfusion, 2021, , 1-3.   | 0.6        | 1         |
| 87 | Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience. Blood, 2014, 124, 5655-5655.  | 1.4        | 1         |
| 88 | Italian Cytometry Society (GIC) endorsement of consensus recommendations for measurable residual disease in chronic lymphocytic leukemia. International Journal of Laboratory Hematology, 2022, 44, .                                       | 1.3        | 1         |
| 89 | Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?. Hematological Oncology, 2022, 40, 835-842.   | 1.7        | 1         |
| 90 | Combined fine needle cytology and flow cytometry immunophenotyping for diagnosis of lymphoid disorders. Leukemia and Lymphoma, 2008, 49, 1212-1213.   | 1.3        | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Long-term follow up of frontline therapy with fludarabine and cyclophosphamide in chronic lymphocytic leukemia: impact of biological parameters on clinical outcome. <i>Annals of Hematology</i> , 2013, 93, 1261-2.                           | 1.8 | 0         |
| 92  | More on spontaneous regression of chronic lymphocytic leukemia: two new cases and potential role of lamivudine in a further patient with advanced disease and hepatitis B virus infection. <i>Leukemia and Lymphoma</i> , 2014, 55, 1955-1957. | 1.3 | 0         |
| 93  | Alemtuzumab and Treatment of Chronic Lymphocytic Leukemia and Its Immune-Related Disorders: One Player on Two Tables. <i>Acta Haematologica</i> , 2014, 132, 237-239.  | 1.4 | 0         |
| 94  | Unusual Hypergranular Myelomatous Plasma Cells. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 617-618.   | 0.6 | 0         |
| 95  | Pseudomembranous colitis in acute lymphoblastic leukaemia. <i>Postgraduate Medical Journal</i> , 2018, 94, 361-361.  | 1.8 | 0         |
| 96  | LDH as Predictive Parameter in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S213.   | 0.4 | 0         |
| 97  | Leg Type Primary Cutaneous Diffuse Large B-Cell Lymphoma. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 378-379.   | 0.6 | 0         |
| 98  | Successful Engraftment of Autologous CD34+ Stem Cells after High-Dose Therapy and Fixed Dose (6) Tj ETQq0 0 0 rgBT /Overlock 10 TF   | 1.4 | 0         |
| 99  | Abstract 2302: The extracellular form of NAMPT contributes to creating a proinflammatory environment in chronic lymphocytic leukemia.. , 2013, , .   |     | 0         |
| 100 | Functional Effects Of NOTCH1 Mutations In Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2013, 122, 4117-4117.  | 1.4 | 0         |
| 101 | Efficacy and Safety Of Bendamustine In Combination With Rituximab For Elderly Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia. A Retrospective Multicenter Study. <i>Blood</i> , 2013, 122, 5309-5309.                  | 1.4 | 0         |
| 102 | SLAMF1/CD150 Activates Autophagy in Chronic Lymphocytic Leukemia Cells, Modulating Chemotaxis and Responses to Therapy. <i>Blood</i> , 2015, 126, 1728-1728.   | 1.4 | 0         |
| 103 | Mutations at 3' Untranslated Region (3'UTR) of NOTCH1 Are Associated with Low CD20 Expression Levels in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 306-306.   | 1.4 | 0         |
| 104 | Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. <i>Blood</i> , 2016, 128, 3240-3240.                                     | 1.4 | 0         |
| 105 | Characterization and Prognostic Relevance of Circulating Microvesicles in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4375-4375.   | 1.4 | 0         |
| 106 | Lack of Prognostic Significance of the Conventional and Novel Prognostic Markers in Trisomy 12 Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 4354-4354.  | 1.4 | 0         |
| 107 | Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study. <i>Blood</i> , 2016, 128, 4494-4494.      | 1.4 | 0         |
| 108 | Comprehensive Characterization of NOTCH1 Mutational Status in Chronic Lymphocytic Leukemia: Clinical Relevance of Subclonal Mutations and Mutation Types. <i>Blood</i> , 2016, 128, 3195-3195.   | 1.4 | 0         |